Nabla vs SigTuple

Nabla has a disclosed valuation of $180M, while SigTuple's valuation is not publicly available, making a direct size comparison difficult. Nabla employs 80 people.

Nabla has raised more in total funding at $30M, compared to SigTuple's $20M — a gap of $10M. Combined, the two companies have completed 1 known funding rounds.

Nabla holds the higher Awaira Score at 73/100, compared to SigTuple's 60/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 13-point gap that reflects meaningful differences in scale or traction.

Nabla was founded by Alexandre Lebrun in 2018. SigTuple was founded by Rohit Kumar Pandey in 2015. Visit each company's profile on Awaira for a full founder biography.

Nabla: Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows. The company has raised $30M in total funding and operates at Series B stage with a valuation of $200M. Nabla's core offering focuses on AI-powered clinical documentation tools designed to reduce administrative burden on healthcare providers. The platform leverages natural language processing and machine learning to automate medical note-taking, allowing physicians to spend more time with patients rather than on paperwork. The company targets hospitals, clinics, and healthcare systems across Europe, with particular strength in the French market. Nabla's technology integrates with existing electronic health record systems and clinical workflows. The company competes in the growing digital health and healthcare AI sector alongside players focused on clinical automation and documentation efficiency. Nabla's approach emphasizes practical integration into existing healthcare infrastructure rather than building standalone applications. The company has demonstrated traction in European healthcare markets where administrative burden on clinicians remains significant. Its Series B funding stage indicates successful product-market fit validation and positions Nabla for expanded market reach and product development in the healthcare AI space. Nabla addresses the specific pain point of clinical documentation burden through AI automation, allowing European healthcare providers to improve operational efficiency. SigTuple: SigTuple develops AI-powered automated pathology solutions that digitize and analyze microscopy slides for blood, urine, sputum, and semen samples, enabling high-throughput diagnostic testing without the constant presence of trained pathologists. The company's AI-Minth platform uses robotic sample preparation, high-resolution imaging, and deep learning analysis to deliver diagnostic-grade results.\n\nThe company raised approximately $20M in Series B funding and has deployed its automated microscopy systems at diagnostic labs, hospitals, and blood banks across India, processing millions of diagnostic samples. SigTuple has received regulatory approvals for its diagnostic AI products and has established partnerships with major diagnostic laboratory chains.\n\nIndia faces a severe shortage of qualified pathologists relative to population, creating an acute need for AI-assisted diagnostic automation. SigTuple's approach of combining hardware, robotics, and AI in an integrated system addresses the complete diagnostic workflow rather than just the software layer, creating higher deployment barriers but also higher switching costs and stronger network effects from accumulated diagnostic data.

SigTuple was founded first in 2015, giving it 3 years of additional market experience. Nabla was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Nabla has approximately 80 employees, while SigTuple has approximately 100-500. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Nabla and SigTuple are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.